Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
113.46
+5.39 (4.99%)
At close: Oct 20, 2026, 4:00 PM EDT
114.31
+0.85 (0.75%)
Pre-market: Oct 21, 2026, 4:49 AM EDT
Kymera Therapeutics Employees
Kymera Therapeutics had 273 employees as of June 30, 2026. The number of employees increased by 55 or 25.23% compared to the same quarter last year. That makes Kymera Therapeutics the 24,569th largest employer in the world and 3,147th in the United States.
Employees
273
Change
55
Growth
25.23%
Revenue / Employee
$384,615
Profits / Employee
-$1,097,440
Market Cap
9.43B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 273 | 55 | 25.23% |
| Mar 31, 2026 | 253 | 45 | 21.63% |
| Dec 31, 2025 | 238 | 50 | 26.60% |
| Sep 30, 2025 | 225 | 41 | 22.28% |
| Jun 30, 2025 | 218 | 37 | 20.44% |
| Mar 31, 2025 | 208 | 22 | 11.83% |
| Dec 31, 2024 | 188 | 1 | 0.53% |
| Sep 30, 2024 | 184 | -8 | -4.17% |
| Jun 30, 2024 | 181 | 0 | - |
| Mar 31, 2024 | 186 | 12 | 6.90% |
| Dec 31, 2023 | 187 | 20 | 11.98% |
| Sep 30, 2023 | 192 | 23 | 13.61% |
| Jun 30, 2023 | 181 | 21 | 13.13% |
| Mar 31, 2023 | 174 | 31 | 21.68% |
| Dec 31, 2022 | 167 | 26 | 18.44% |
| Sep 30, 2022 | 169 | 33 | 24.26% |
| Jun 30, 2022 | 160 | 48 | 42.86% |
| Mar 31, 2022 | 143 | 51 | 55.43% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Axsome Therapeutics | 1,346 |
| Twist Bioscience | 979 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| TG Therapeutics | 399 |
KYMR News
- 12 days ago - Kymera Therapeutics initiated with an Outperform at Raymond James - TheFly
- 16 days ago - Citi adds ‘upside 90-day catalyst watch’ on Kymera Therapeutics - TheFly
- 16 days ago - Kymera Therapeutics price target raised to $150 from $135 at Citi - TheFly
- 19 days ago - JPMorgan SMid biotech analysts hold an analyst/industry conference call - TheFly
- 22 days ago - Kymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan - TheFly
- 26 days ago - Kymera Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 27 days ago - Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs - TheFly
- 4 weeks ago - Kymera Therapeutics price target raised to $152 from $132 at Stifel - TheFly